tag:blogger.com,1999:blog-58826830516616593302012-01-23T04:31:05.251-08:00LNnoreply@blogger.comBlogger3351100tag:blogger.com,1999:blog-5882683051661659330.post-34726041718477949772010-12-21T18:21:00.000-08:002010-12-21T18:23:17.536-08:00

Older men with high-risk prostate cancer frequently are offered fewer – and less effective – choices of treatment than younger men, potentially resulting in earlier deaths, according to a new UCSF study.The scientists found that men above age 75 with high-risk prostate cancer often are under-treated through hormone therapy or watchful waiting alone in lieu of more aggressive treatments such as

LNnoreply@blogger.com1tag:blogger.com,1999:blog-5882683051661659330.post-44948741716819894642010-12-16T19:04:00.000-08:002010-12-16T19:05:38.749-08:00

The PSA screening test for prostate cancer is not perfect. It can indicate cancer when none is present and miss life-threatening tumors. But a new study suggests the test is more reliable in men taking dutasteride (Avodart®), a drug widely prescribed to shrink an enlarged prostate gland.Dutasteride lowers PSA levels by about half within six months. But the researchers found that even a slight

LNnoreply@blogger.com3tag:blogger.com,1999:blog-5882683051661659330.post-77231791521720939572010-12-02T19:29:00.000-08:002010-12-02T19:30:05.131-08:00

A protein that is crucial for regulating the self-renewal of normal prostate stem cells, needed to repair injured cells or restore normal cells killed by hormone withdrawal therapy for cancer, also aids the transformation of healthy cells into prostate cancer cells, researchers at UCLA have found.The findings, by researchers with the Eli and Edythe Broad Center of Regenerative Medicine and Stem

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-70838953571877218562010-12-02T19:26:00.000-08:002010-12-02T19:27:52.186-08:00

Austrian researchers have uncovered mutations throughout the mitochondrial genome that are associated with prostate cancer. An exciting aspect of the study, published by Cell Press on December 2 in the American Journal of Human Genetics, is the association of tRNA mutations with elevated levels of prostate-specific antigen (PSA) in Austrian men diagnosed with various stages of prostate

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-17091096722370755812010-12-02T18:47:00.000-08:002010-12-02T18:48:50.266-08:00

A UCSF research collaboration with GE Healthcare has produced the first results in humans of a new technology that promises to rapidly assess the presence and aggressiveness of prostate tumors in real time, by imaging the tumor's metabolism.This is the first time researchers have used this technology to conduct real-time metabolic imaging in human patients and represents a revolutionary approach

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-19424882338895611522010-11-29T19:49:00.000-08:002010-11-29T19:50:21.077-08:00

A UCSF research collaboration with GE Healthcare has produced the first results in humans of a new technology that promises to rapidly assess the presence and aggressiveness of prostate tumors in real time, by imaging the tumor's metabolism.This is the first time researchers have used this technology to conduct real-time metabolic imaging in a human patient and represents a revolutionary approach

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-31870092911940845622010-11-15T18:49:00.000-08:002010-11-15T18:50:57.827-08:00

Men treated with hormone-based therapy for prostate cancer faced a 30 percent to 40 percent higher risk of colorectal cancer, compared to patients who did not receive this treatment, according to a new study. The study looked at use of androgen deprivation therapy, a common type of treatment for prostate cancer that involves blocking the male hormone testosterone through either surgical removal

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-27587674638896721102010-11-08T18:38:00.000-08:002010-11-08T18:39:50.512-08:00

Northwestern Medicine researchers at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University have found that a new, nontoxic drug made from a chemical in soy could prevent the movement of cancer cells from the prostate to the rest of the body. These findings will be presented at the Ninth Annual American Association for Cancer Research Frontiers in Cancer Prevention Research

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-27740580389651783192010-10-27T07:38:00.000-07:002010-10-27T07:41:43.345-07:00

A new British review of existing research suggests that while a newer type of radiation for the treatment of prostate cancer does not help patients live longer compared to an older type – at least when similar doses are given − it does appear to reduce gastrointestinal side effects.The newer type of radiation, known as intensity-modulated radiotherapy, has become common in the United States.

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-83427718775508646502010-10-20T17:09:00.000-07:002010-10-20T17:10:33.649-07:00

The U.S. Food and Drug Administration today asked manufacturers to add new warnings to labeling of gonadotropin-releasing hormone (GnRH) agonists, a class of drugs primarily used to treat men with prostate cancer.The warnings would alert patients and their health care professionals to the potential risk of heart disease and diabetes in men treated with these medications. In May, the FDA said that

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-79395289223304008612010-10-19T08:26:00.000-07:002010-10-19T08:27:35.608-07:00

Survival rates of the world's most common cancer might soon be increased with a new vitamin E treatment which could significantly reduce tumour regrowth.Queensland University of Technology (QUT) prostate cancer researchers are leading the fight against a disease which kills 3000 Australian men a year.Dr Patrick Ling, whose research will be a centrepiece of the new $354 million Translational

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-49822148066854656352010-10-18T07:56:00.000-07:002010-10-18T07:57:35.840-07:00

A first-ever, long-term study of patients who underwent robot-assisted surgery to remove their cancerous prostates found that nearly 87 percent of them had no recurrence of the disease after five years.The findings were reported in this month's issue of the European Urology journal by a team of Henry Ford Hospital researchers led by Mani Menon, M.D., an internationally recognized pioneer in the

LNnoreply@blogger.com1tag:blogger.com,1999:blog-5882683051661659330.post-55573188404902990602010-10-15T07:58:00.001-07:002010-10-15T07:59:58.581-07:00

New research led by UK scientists has shown that a protein in urine could be a reliable marker for prostate cancer risk, and although there is still a lot of work to be done to move it from the laboratory to the clinic, the finding is raising hopes that an easy and reliable clinical test for prostate cancer is now much closer.The study, led by scientists from the Cancer Research UK (CRUK)

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-32301796378844568502010-10-15T07:56:00.000-07:002010-10-15T07:57:36.655-07:00

In the first-of-a-kind clinical trial, a robot will be used to place therapeutic radioactive seeds in prostate cancer patients. The National Cancer Institute-supported study, which will enroll 14 patients, has just opened at Thomas Jefferson University Hospital.The robot has been designed by Thomas Jefferson University scientists to provide the steadiest and most precise method possible to

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-60556190936961913132010-10-08T07:21:00.000-07:002010-10-08T07:22:06.553-07:00

Using novel technology allowing "virtual bone biopsies" researchers have found that a common treatment for prostate cancer called androgen deprivation therapy (ADT) is associated with structural decay of cortical and trabecular bone. The study has been accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).Prostate cancer is the second most

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-35089342541141212892010-09-30T06:58:00.000-07:002010-09-30T07:00:15.022-07:00

According to early findings of a pilot study presented at a conference in the US this week, the controversy surrounding prostate cancer screening could be about to change: a UK company has developed a panel of biomarkers that appears to distinguish samples of prostate cancer from samples of benign prostate disease and healthy prostate tissue 90 per cent of the time, considerably higher than

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-71301880171338801202010-09-29T20:57:00.000-07:002010-09-29T21:01:35.675-07:00

• Earlier PSA detection could affirm that cancer is “cured” or needs earlier treatment.• Test is 1,000 to 10,000 times more sensitive than leading PSA tests.• Able to measure PSA in all blood samples previously categorized as “below detection levels.” A new test could reliably detect early increases in prostate specific antigen (PSA) levels — a biomarker commonly used to measure the recurrence of

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-29292307496121617272010-09-28T20:15:00.000-07:002010-09-28T20:18:14.810-07:00

Patients with the most aggressive form of prostate cancer who have surgery - radical prostatectomy - were found to have a 10-year cancer-specific survival rate of 92%, which is high, and a 77% overall survival rate, according to researchers from the Fox Chase Cancer Center and the Mayo Clinic, USA. This compares to an 88% 10-year cancer specific survival rate and 52% overall survival rate for

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-19749334696540423952010-09-13T07:16:00.000-07:002010-09-13T07:17:49.307-07:00

Men aged 55 to 74 years who have low baseline blood levels of prostate specific antigen (PSA) are not likely to benefit from further screening and treatment. That is the conclusion of a new study published early online in Cancer, a peer-reviewed journal of the American Cancer Society. The aim of the study is to help physicians and patients weigh the pros and cons of prostate cancer screening and

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-63581453257304734252010-08-23T07:54:00.000-07:002010-08-23T07:55:50.188-07:00

A new analysis has found that short-term and long-term costs of prostate cancer care vary considerably based on which treatment strategy a man initially receives. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the study finds that treatments that may be less expensive in the short-term may have higher long-term costs.For men with early stage prostate

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-88887826335566501662010-08-06T07:37:00.000-07:002010-08-06T07:40:05.495-07:00

Surgery for localized prostate cancer offers a significantly higher survival rate than either external-beam radiation or hormonal therapies, according to a new study led by researchers at UCSF.The differences among therapies were more prominent at higher levels of cancer risk, and suggest, the researchers say, that in many cases surgery should play a greater role in treatment strategies for

LNnoreply@blogger.com1tag:blogger.com,1999:blog-5882683051661659330.post-80628703295095938422010-07-29T20:48:00.000-07:002010-07-29T20:50:16.794-07:00

With a recent first of its kind surgery, physicians at Mayo Clinic in Arizona have developed a new surgical procedure for the treatment of prostate cancer using natural orifices - signaling the next step in the evolution of minimally invasive surgery. Removing the prostate is a common treatment for patients with prostate cancer, which affects one in six men in the U.S. according to the American

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-23338947527437445882010-07-28T19:44:00.000-07:002010-07-28T19:45:49.175-07:00

Men who develop prostate cancer, especially the more aggressive and dangerous forms that spread throughout the body, tend to retain denser bones as they age than men who stay free of the disease, suggests new research from Johns Hopkins and the National Institute on Aging (NIA), part of the National Institutes of Health.The finding, published in the July British Journal of Urology International,

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-25958206494173355222010-07-28T07:31:00.000-07:002010-07-28T07:32:44.477-07:00

A new report published in the July 26 issue of Archives of Internal Medicine claims many men who are diagnosed with prostate cancer undergo aggressive therapy, even when they have low PSA scores and low-risk disease, saying "these results underscore the fact that PSA level, the current biomarker, is not a sufficient basis for treatment decisions.""When it comes to 'overtreatment,' the PSA test is

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-35511032366067402992010-07-24T21:03:00.000-07:002010-07-24T21:05:14.669-07:00

Prostate Specific Antigen (PSA), the primary means of diagnosing prostate cancer in the modern era, lacks specificity in differentiating benign from malignant disease. Thus clinical decisions based on PSA may lead to unnecessary biopsies in some while overlooking biopsies in others. p2PSA has emerged from studies looking at archived serum samples over the past several years as a better screening

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-15017995733453804762010-07-21T08:11:00.000-07:002010-07-21T08:13:02.058-07:00

Prostate cancer advances when tumors become resistant to hormone therapy, which is the standard treatment for patients, and begin producing their own androgens.Researchers at UT Southwestern Medical Center have found that blocking one of the enzymatic steps that allow the tumor to produce androgens could be the key in halting a tumor's growth.Read more at Medical News Today.

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-21960972446336777212010-07-13T07:25:00.000-07:002010-07-13T07:27:32.312-07:00

Men with prostate cancer lose significantly less bone mineral content (BMC) as they age than men who are free of the disease, according to research in the July issue of BJUI. The findings are important because loss of BMC can play a key role in the development of fragile bones, fractures and osteoporosis.American researchers studied 519 participants who joined the Baltimore Longitudinal Study at

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-31923577347403632592010-06-24T22:48:00.000-07:002010-06-24T22:49:40.872-07:00

Ensuring the optimum radiation dose on the same day as the brachytherapy implant in prostate cancer treatment manages to control the illness in about 95% of the cases. This is the result of research undertaken at the University Hospital of Navarre and published in the latest issue of Brachytherapy, journal of the American Society of Brachytherapy. As is known, brachytherapy is a radiotherapy

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-75622051269772101492010-06-19T22:58:00.000-07:002010-06-19T22:59:47.068-07:00

A study presented earlier this month at a meeting of the American Urological Association by a team of French researchers found that a particular dog breed, Belgian Malinois shepherd dogs, can be trained to detect prostate cancer.Doctors at Paris's Hospital Tenon trained the dogs to distinguish between the smell of urine from men with prostate cancer and those without it. At the end of the

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-32502154903985271252010-06-13T12:56:00.000-07:002010-06-13T12:58:24.431-07:00

Researchers from Case Western Reserve University School of Dental Medicine and University Hospitals Case Medical Center report initial results from a small sample that inflammation from gum disease and prostate problems just might be linked. They discuss their new evidence in the Journal of Periodontology, the official journal of the American Academy of Periodontology.The researchers compared two

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-80092272940731398992010-06-09T18:51:00.000-07:002010-06-09T18:52:36.952-07:00

In what could lead to a major advance in the treatment of prostate cancer, scientists now know exactly why polyphenols in red wine and green tea inhibit cancer growth. This new discovery, published online in The FASEB Journal (http://www.fasebj.org), explains how antioxidants in red wine and green tea produce a combined effect to disrupt an important cell signaling pathway necessary for prostate

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-55233217761202593372010-06-08T19:06:00.000-07:002010-06-08T19:07:24.393-07:00

Johns Hopkins experts have found that men enrolled in an active surveillance program for prostate cancer that eventually needed surgery to remove their prostates fared just as well as men who opted to remove the gland immediately, except if a follow-up biopsy during surveillance showed high-grade cancer.Active surveillance, or "watchful waiting," is an option open to men whose tumors are

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-35193298072236882112010-06-08T19:05:00.001-07:002010-06-08T19:06:02.447-07:00

A blood vessel-blocking drug called tasquinimod slowed the rate of disease progression in a clinical trial of 200 prostate cancer patients, according to experts at Johns Hopkins, Roswell Park Cancer Institute and Duke University.Tasquinimod is a so-called "anti-angiogenesis" drug that squeezes off blood supply to prostate tumors by blocking new blood vessel development. Tumors require these vast

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-35624626637145464322010-06-07T06:55:00.000-07:002010-06-07T06:56:36.915-07:00

Findings of a clinical trial reported at SNM's 57th Annual Meeting indicate that a new molecular imaging agent could improve diagnosis of recurrent prostate cancer and determine the best possible course of treatment for patients."Despite definitive treatment, about 30 percent of prostate cancers recur," said David Schuster, M.D., director of the division of nuclear medicine and molecular imaging

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-45368978216686369532010-05-29T23:31:00.000-07:002010-05-29T23:33:30.094-07:00

A 17-year-long community study looking at symptoms of enlarged prostate in over 2,000 men age 40 to 79 years suggests that surgery for benign prostatic hyperplasia (BPH) offers more relief from incontinence and obstruction symptoms than treatment from drug-based therapy, according to a new study by researchers at Mayo Clinic. The researchers presented their results today at the annual meeting of

LNnoreply@blogger.com1tag:blogger.com,1999:blog-5882683051661659330.post-19650276399467270712010-05-25T19:09:00.000-07:002010-05-25T19:10:05.119-07:00

Quanterix Corporation, the single molecule diagnostics company focused on developing and commercializing high sensitivity tests, announced the publication of a breakthrough study of the company's proprietary technology that demonstrates an unprecedented sensitivity for measuring a biomarker for prostate cancer recurrence. The research article, featured on the cover of the June issue (Volume 28,

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-40462015102413786532010-05-22T11:13:00.000-07:002010-05-22T11:15:09.023-07:00

Today is an exciting day for men with advanced prostate cancer and the millions of families and loved ones who are profoundly affected. Today a new prostate cancer treatment option, Provenge, was approved by the Food and Drug Administration (FDA).Read more at Medical News Today.

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-91192421619481221272010-05-22T11:09:00.000-07:002010-05-22T11:13:20.075-07:00

Researchers at Columbia University recently analyzed the positive effects of Modified Citrus Pectin (MCP) on human and mouse prostate cancer cell lines. The results, as reported by lead researcher Dr. Aaron Katz in the online-first publication of Integrative Cancer Therapies, show that MCP inhibits cell proliferation and induces apoptosis (programmed cell death) in both androgen-dependent and

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-67849290797228004492010-05-18T07:46:00.000-07:002010-05-18T07:47:55.947-07:00

In the July issue of European Urology, the scientific journal of the European Association of Urology (EAU), S. Eggener et al. discussed in a recent study the significance and impact of focal therapy for low-risk cancer patients.Since the introduction of prostate cancer screening based on prostate-specific antigen (PSA), over-treatment has increased. A significant proportion of patients diagnosed

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-91240726259933242992010-05-06T07:36:00.000-07:002010-05-06T07:37:48.903-07:00

Preliminary review suggests an increase in the risk of diabetes and certain cardiovascular diseases in men treated with GnRH agonistsGonadotropin-Releasing Hormone (GnRH) agonists, a class of medications primarily used to treat men with prostate cancer, have been associated with a small increased risk for diabetes, heart attack, stroke, and sudden death in men treated with one of the medications,

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-38167127374489722692010-05-05T07:29:00.000-07:002010-05-05T07:30:51.940-07:00

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) announced that development of its GVAX Prostate Cancer Vaccine (GVAX Prostate) for the treatment of prostate cancer has been reinitiated. Manufacturing of new GVAX Prostate is in process, regulatory steps to lift the GVAX Prostate clinical hold prior to trial initiation are being taken, and prostate cancer patients are expected to be treated in a

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-65926056876758588642010-04-29T19:04:00.001-07:002010-04-29T19:04:56.723-07:00

Today’s announcement that the U.S. Food and Drug Administration has approved Provengeâ, a new form of therapy for some prostate cancer patients, marks the beginning of an era in which patients’ own immune systems become part of the standard therapeutic arsenal against cancer, say Dana-Farber Cancer Institute investigators who led a study of the treatment’s effectiveness in patients.Read more at

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-40685948882112948022010-04-22T07:11:00.000-07:002010-04-22T07:12:24.624-07:00

ASTRO President Anthony Zietman, M.D., spoke before the Medicare Evidence Development and Coverage Advisory Committee (MEDCAC) meeting today on radiation therapy for treatment of localized prostate cancer. MEDCAC provides advice and recommendations to the Centers for Medicare and Medicaid Services for what is covered by Medicare and Medicaid, based on scientific evidence. Today's meeting focused

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-24236849466125525042010-04-20T21:16:00.000-07:002010-04-20T21:17:38.171-07:00

Cold, dry weather has been linked to an increased incidence of prostate cancer. Researchers writing in BioMed Central's open access International Journal of Health Geographics suggest that meteorological effects on persistent organic pollutants, such as some pesticides and industrial by-products, may be to blame.Sophie St-Hilaire worked with a team of researchers from Idaho State University, USA,

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-31511284137571492782010-04-16T19:12:00.000-07:002010-04-16T19:13:31.929-07:00

The American Cancer Society estimates one man in six will get prostate cancer during his lifetime, making it the second-leading cause of cancer death in men. With a new partnership with Areva Med, UC researchers will investigate the use of a new drug in stopping the growth of prostate cancer tumors.In the study, UC researchers in the lab of Zhongyun Dong, PhD, will test the efficacy of a new

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-45176405955377402432010-04-16T07:59:00.000-07:002010-04-16T08:01:19.818-07:00

A new study of almost 700 patients from The Mount Sinai Medical Center shows that prostate cancer patients who had robotically assisted prostatectomy enjoyed significant benefits over patients who had a traditional open radical prostatectomy, including decreased surgical and recovery time, less blood loss during surgery and significantly shorter hospital stays. The study, by David B. Samadi, MD,

LNnoreply@blogger.com1tag:blogger.com,1999:blog-5882683051661659330.post-24692883663605179402010-04-01T18:55:00.000-07:002010-04-01T18:56:38.157-07:00

Van Andel Research Institute (VARI) scientists have determined how two proteins required for the initiation and development of prostate cancer interact at the molecular level, which could lead to improved treatments for the disease.One of the proteins, androgen receptor, is already an important drug target for prostate cancer. The other, steroid receptor coactivator-3 (SRC3), was originally

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-11429782014350764402010-03-27T23:47:00.000-07:002010-03-27T23:48:16.432-07:00

Radiotherapy Centers of Georgia (RCOG), a division of RC Cancer Centers announced that they have reached a new milestone and recently treated their 12,500th patient for prostate cancer with their ProstRcision® treatment therapy. The milestone means their treatment database is one of the most comprehensive in the nation. Available exclusively from RC Cancer Centers, ProstRcision® has the

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-35901355109876618962010-03-20T11:16:00.000-07:002010-03-20T11:17:39.277-07:00

The U.S. Department of Veterans Affairs (VA) is being fined for botching 97 of 116 procedures to treat prostate cancer among men seeking care at the agency's medical center in Philadelphia. Although the punishment, which adds up to a mere $227,500, might not sound like more than a slap on the wrist, it is coming from the Nuclear Regulatory Commission (NRC) and is one of the largest the commission

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-76881391124693413782010-03-19T07:34:00.000-07:002010-03-19T07:36:05.548-07:00

New research has revealed a major breakthrough in the use of cough medicine ingredient noscapine as a prophylactic treatment for prostate cancer.The study shows that noscapine inhibited tumor growth in mice and also limited the spread of tumors without causing any side effects.The collaborative pre-clinical laboratory research was conducted by Dr. Israel Barken, of the Prostate Cancer Research

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-89211577021430679562010-03-11T18:47:00.000-08:002010-03-11T18:49:31.129-08:00

Van Andel Research Institute (VARI) researchers have developed a new method to better study the cells that line and protect the prostate in relation to the development of cancer. Using the model, they found that normal cells and cancer cells depend on different factors to survive, which could aid in discovering how to target cancer cells without affecting normal cells when developing

LNnoreply@blogger.com2tag:blogger.com,1999:blog-5882683051661659330.post-90481946852270545882010-03-10T07:24:00.000-08:002010-03-10T07:25:44.433-08:00

Shahriar Koochekpour, MD, PhD, Assistant Professor of Microbiology and Immunology, Biochemistry and Molecular Biology, and Genetics at LSU Health Sciences Center New Orleans, led research that has discovered, for the first time, a genetic mutation in African-American men with a family history of prostate cancer who are at increased risk for the disease. Dr. Koochekpour, who is also a member of

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-47186979576971126752010-02-25T20:33:00.000-08:002010-02-25T20:37:50.383-08:00

Monash University biomedical scientists have identified a new way to treat castrate resistant cells in prostate cancer sufferers – the most common cancer in Australian men.For more than 60 years the main way to treat men with prostate cancer has involved removing the hormones that fuel growth of the cancer cells. Although initially effective this treatment inevitably fails and when the tumour

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-22958638415155676082010-02-25T07:07:00.000-08:002010-02-25T07:08:08.236-08:00

The introduction of prostate-specific antigen (PSA) testing as a screening tool for early detection of prostate cancer (PCa) in the beginning of the 1990s drastically increased the detection of PCa. The risk of suicide is increased among cancer patients including men with PCa. To assess the risk of suicide among men diagnosed with PCa subsequent to PSA testing, a nation-wide study was carried out

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-1779987946803228552010-02-02T14:49:00.000-08:002010-02-02T14:51:17.710-08:00

Prostate cancer cells are more likely to spread to other parts of the body if a specific gene quits functioning normally, according to new data from researchers at UT Southwestern Medical Center.Certain prostate cancer cells can be held in check by the DAB2IP gene. The gene’s product, the DABIP protein, acts as scaffolding that prevents many other proteins involved in the progression of prostate

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-87681784650679064252010-01-05T07:31:00.001-08:002010-01-05T07:31:58.337-08:00

Sexual function in prostate cancer patients receiving external beam radiation therapy (EBRT) decreases within the first two years after treatment but then stabilizes and does not continuously decline as was previously thought, according to a study in the January 1 issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Radiation

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-70984264331497451402010-01-03T22:30:00.000-08:002010-01-03T22:33:00.913-08:00

An experimental drug currently being tested against breast and lung cancer shows promise in fighting the brain cancer glioblastoma and prostate cancer, researchers at UT Southwestern Medical Center have found in two preclinical studies.Read more at Machines Like Us.

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-67656564553727144392009-12-26T10:54:00.000-08:002010-01-03T22:30:34.922-08:00

Varicocele has only recently been shown to be a bilateral disease, the primary cause for male infertility and low testosterone level. It has now for the first time been discovered to be the cause of enlargement of the prostate and for the development of prostatic cancer as well. Also, for the first time in the published medical literature, it has been proven that super-selective venography and

LNnoreply@blogger.com27tag:blogger.com,1999:blog-5882683051661659330.post-86996617750162457372009-12-09T07:13:00.000-08:002009-12-09T07:16:05.396-08:00

The natural compound xanthohumol blocks the effects of the male hormone testosterone, therefore aiding in the prevention of prostate cancer.“We hope that one day we can demonstrate that xanthohumol prevents prostate cancer development, first in animal models and then in humans, but we are just at the beginning,” said Clarissa Gerhauser, Ph.D., group leader of cancer chemoprevention in the

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-21635124324491914132009-12-08T18:20:00.000-08:002009-12-08T18:22:04.934-08:00

Women were the beneficiaries of the first cancer vaccine―Gardasil, approved in 2006 to prevent cervical cancer. Several weeks ago, the same drug was made available to young males to prevent genital warts. And now it looks as if the first vaccine approved to fight cancer, by enhancing the body's immune response to cancer cells, will benefit males. Last month the Food and Drug Administration

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-88145878853910881652009-12-08T06:28:00.000-08:002009-12-08T06:29:32.615-08:00

As little as 15 minutes of exercise a day can reduce overall mortality rates in patients with prostate cancer, according to findings presented at the American Association for Cancer Research Frontiers in Cancer Prevention Research Conference, held here, Dec. 6-9, 2009. "We saw benefits at very attainable levels of activity," said Stacey A. Kenfield, Sc.D., epidemiology research associate at the

LNnoreply@blogger.com15tag:blogger.com,1999:blog-5882683051661659330.post-30134514219989223252009-12-02T21:31:00.000-08:002009-12-02T21:33:11.348-08:00

Prostate cancer patients who have a prostate-specific antigen (PSA) value of less than or equal to 1.5 at two years after external beam radiation therapy (EBRT) are less likely to have a cancer recurrence and cancer-related death, according to a study in the December 1 issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for

LNnoreply@blogger.com1tag:blogger.com,1999:blog-5882683051661659330.post-41536797352569838082009-11-06T18:31:00.000-08:002009-11-06T18:32:16.060-08:00

Researchers at Wake Forest University School of Medicine and the University of Wisconsin-Madison have discovered that some elevated prostate-specific antigen (PSA) levels in men may be caused by a hormone normally occurring in the body, and are not necessarily a predictor of the need for a prostate biopsy.Elevated levels of PSA have traditionally been seen as a potential sign of prostate cancer,

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-21208365165947791092009-11-04T19:05:00.001-08:002009-11-04T19:05:54.042-08:00

Researchers in the Oregon Health & Science University Knight Cancer Institute and the Portland Veterans Affairs Medical Center have found a combination of radiation therapy and chemotherapy given before prostate removal is safe and may have the potential to reduce cancer recurrence and improve patient survival.Their findings were presented this week at the 51st annual meeting of the American

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-41652236126275147752009-11-03T19:35:00.001-08:002009-11-03T19:35:53.880-08:00

A diagnosis of prostate cancer raises the question for patients and their physicians as to how the tumor will behave. Will it grow quickly and aggressively and require continuous treatment, or slowly, allowing therapy and its risks to be safely delayed?The answer may lie in the size and shape of the blood vessels that are visible within the cancer, according to research led by investigators at

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-50625101964948168702009-11-02T19:49:00.000-08:002009-11-02T19:50:02.759-08:00

Radiation dose delivered to the prostate and nearby organs in every brachytherapy procedure should be carefully analyzed using post-implant CT or MRI and uniformly documented in every patient, according to a new guideline co-authored by Yan Yu, Ph.D., director of Medical Physics in the department of Radiation Oncology at Thomas Jefferson University.The guideline was issued by a task group

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-1369078553567576722009-10-28T07:11:00.000-07:002009-10-28T07:12:35.074-07:00

Lifetime physically active men have a lower risk of developing prostate cancer, according to a new study from Karolinska Institutet (KI). The effect was observable in those who had been sitting for less than half their working day or had been physically active for more than an hour a day.Read more at Machines Like Us.

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-79562114366724062742009-10-20T19:11:00.000-07:002009-10-20T19:18:44.974-07:00

Twenty years of screening for breast and prostate cancer – the most diagnosed cancer for women and men – have not brought the anticipated decline in deaths from these diseases, argue experts from the University of California, San Francisco and the University of Texas Health Science Center at San Antonio in an opinion piece published in the Journal of the American Medical Association.Instead,

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-15199857894025712282009-10-08T20:23:00.001-07:002009-10-08T20:23:49.653-07:00

Conventional techniques to diagnose and monitor prostate cancer are known to be very reliable, but doctors may soon have a new hi-tech tool in their arsenal.

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-35132922558025909442009-09-28T19:02:00.000-07:002009-09-28T19:05:26.718-07:00

Men largely make decisions about prostate cancer screening based on conversations with their clinicians, but these discussions often do not include information about the risks of testing in addition to the benefits, according to a report in the September 28 issue of Archives of Internal Medicine, one of the JAMA/Archives journals. A second report in the same issue uses statistical modeling to

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-59241353575758261042009-09-28T07:35:00.001-07:002009-09-28T07:35:50.670-07:00

University of Toronto researchers have used nanomaterials to develop a microchip sensitive enough to quickly determine the type and severity of a patient's cancer so that the disease can be detected earlier for more effective treatment.Read more at Machines Like Us.

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-20564009852341115152009-09-25T21:21:00.000-07:002009-09-25T21:22:32.530-07:00

In 2009, it is estimated that 192,280 new cases will be diagnosed and more than 27,000 men will die of prostate cancer. The lifetime probability of developing prostate cancer is one in six for American men. Current treatment alternatives for clinically localized prostate cancer include removal of the prostate gland (surgery), radiation to the cancerous prostate (external beam or radioactive seed

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-7728783630233529132009-09-25T06:47:00.000-07:002009-09-25T06:50:06.026-07:00

In the largest study of its kind, the international team of pathologists studied an initial 4,000 prostate cancer patients over a period of 15 years to further understanding into the natural progression of the disease and how it should be managed. The research, published in the British Journal of Cancer, could be used to develop a blood test to distinguish between aggressive and non-aggressive

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-7896570690606618672009-09-22T06:53:00.000-07:002009-09-22T06:56:39.193-07:00

New research has found that hormone therapy used to treat men with advanced prostate cancer is associated with an increased chance of developing various heart problems. Some choices of therapy appear, however, to be less risky than others.Researchers told Europe's biggest cancer congress, ECCO 15 – ESMO 34], in Berlin today (Tuesday 22 September) that the findings of their study, the largest and

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-3479861564780201122009-09-11T19:11:00.000-07:002009-09-11T19:12:57.426-07:00

A team of scientists led by researcher Brenda Hernandez, Ph.D., M.P.H.—an assistant professor at the University of Hawai'i at Mānoa's Cancer Research Center of Hawai'i—has reported that body mass in younger and older adulthood, and weight gain between these life periods, may influence a man's risk for prostate cancer. This risk varies among different ethnic groups, according to findings reported

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-64372499238275086882009-09-10T22:12:00.000-07:002009-09-10T22:17:09.051-07:00

A new type of stem cell discovered in the prostate of adult mice can be a source of prostate cancer, according to a new study by researchers at the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center and NewYork-Presbyterian Hospital.Led by Michael Shen, Ph.D., professor of medicine and genetics and development at Columbia University Medical Center, the researchers

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-31577514894845598952009-09-09T19:58:00.000-07:002009-09-09T19:59:25.601-07:00

Researchers confirmed previous findings that the sexual transmitted infection known as Trichomonas vaginalis is associated with an increased risk of prostate cancer in a study published online September 9 in the Journal of the National Cancer Institute. Jennifer Rider Stark, ScD, of the department of epidemiology at the Harvard School of Public Health in Boston, and colleagues conducted a

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-52593845612313764862009-09-07T17:13:00.000-07:002009-09-07T17:14:46.213-07:00

In a finding with potentially major implications for identifying a viral cause of prostate cancer, researchers at the University of Utah and Columbia University medical schools have reported that a type of virus known to cause leukemia and sarcomas in animals has been found for the first time in malignant human prostate cancer cells. If further investigation proves the virus, XMRV (Xenotropic

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-80630234671137170162009-09-01T19:22:00.001-07:002009-09-01T19:25:07.660-07:00

A new study published in the September issue of The Journal of Nuclear Medicine shows that positron emission tomography (PET)/computer tomography (CT) scans with the imaging agent choline could detect recurring prostate cancer sooner than conventional imaging technologies in some patients who have had their prostates surgically removed. In addition, the journal also includes a paper that provides

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-9525257758965392302009-08-22T23:10:00.000-07:002009-08-22T23:11:24.757-07:00

The correlation between obesity and risk of prostate cancer (CaP) to include the progression of CaP has been an area of significant investigation. Greater height has also been proposed to be a risk factor for CaP, due to increased levels of bioavailable insulin-like growth factors (IGFs) or androgens, or genetic predisposition. This relationship is supported in some but not all studies. In the

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-19234121929629980192009-08-22T11:10:00.000-07:002009-08-22T11:11:41.553-07:00

Elevated insulin levels in the normal range appear to be associated with an increased risk of prostate cancer, according to a new study published online August 21 in the Journal of the National Cancer Institute.Insulin-like growth factors appear to be involved in the development of prostate cancer, but the relationship between circulating insulin levels and prostate cancer risk has been

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-41379187645898930772009-08-15T21:08:00.000-07:002009-08-15T21:09:45.836-07:00

A new look at a large database of prostate cancer patients shows that obesity plays no favorites when it comes to increasing the risk of recurrence after surgery: Being way overweight is equally bad for blacks and whites, say researchers at Duke University Medical Center. Studies have shown that obesity is linked to generally worse outcomes in many cancers, including prostate cancer. Because

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-2253281277748801072009-08-14T19:11:00.000-07:002009-08-14T19:13:40.102-07:00

Researchers at the Keck School of Medicine of the University of Southern California (USC) have identified a novel genetic mechanism that may govern an individual's risk of developing prostate cancer.The findings, published today in the Public Library of Science (PLoS) Genetics journal, found mechanisms involved in cancer-associated sites in areas where no genes are present (gene 'deserts') at a

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-66066441445320097562009-08-13T18:57:00.000-07:002009-08-13T18:59:16.687-07:00

A new look at a large database of prostate cancer patients shows that obesity plays no favorites when it comes to increasing the risk of recurrence after surgery: Being way overweight is equally bad for blacks and whites, say researchers at Duke University Medical Center.Studies have shown that obesity is linked to generally worse outcomes in many cancers, including prostate cancer. Because

LNnoreply@blogger.com1tag:blogger.com,1999:blog-5882683051661659330.post-20463461570438463982009-07-31T23:05:00.000-07:002009-07-31T23:06:09.014-07:00

Democratic Senator Christopher Dodd, a leading force for U.S. healthcare reform, said on Friday he has prostate cancer but still plans to run for re-election next year."I'll be a little leaner and a little meaner but I'm running," Dodd, 65, told a televised news conference in his home state of Connecticut.Read more at Yahoo News.

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-17532269624776394712009-07-29T07:10:00.000-07:002009-07-29T07:12:38.275-07:00

Men who have a regular, ongoing relationship with a health care provider are more likely to receive prostate cancer screening and less likely to be diagnosed with advanced prostate cancer, regardless of their race, according to a University of North Carolina study published in the current issue of the journal Cancer.The study compared the experiences of black and white men over age 50 and newly

LNnoreply@blogger.com1tag:blogger.com,1999:blog-5882683051661659330.post-7516224530068995412009-07-27T06:56:00.000-07:002009-07-27T06:58:17.811-07:00

Men with early stages of prostate cancer who delay radical treatment in favor of an approach of "expectant management" do not have high levels of anxiety and distress. That is the conclusion of a new study published in the September 1, 2009 issue of Cancer, a peer-reviewed journal of the American Cancer Society. The study's results suggest that living with untreated cancer is not upsetting for

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-80607556343499000842009-07-23T19:16:00.000-07:002009-07-23T19:18:54.769-07:00

A study led by researchers at the Ohio State University Comprehensive Cancer Center and Dana-Farber Cancer Institute reveals how late-stage, hormone-independent prostate tumors gain the ability to grow without need of hormones.The onset of hormone-independent growth marks an advanced and currently incurable stage of prostate cancer.The study, published in the July 24, 2009, issue of the journal

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-70747662212091045612009-07-23T19:06:00.000-07:002009-07-23T19:08:32.219-07:00

Researchers from NewYork-Presbyterian Hospital/Weill Cornell Medical Center have discovered a new gene fusion that is highly expressed in a subset of prostate cancers. The results may lead to more accurate prostate cancer testing and new targets for potential treatments. Experts believe that gene fusions — a hybrid gene formed from two previously separated genes — may be at the root of what

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-37098847788307114232009-07-23T18:46:00.000-07:002009-07-23T18:48:34.844-07:00

Eight academic medical centers have been selected by the National Institute of Digestive and Kidney Disease (NIDDK) to study urologic chronic pelvic pain disorders (including prostatitis) by looking for clues outside the bladder and prostate. The total investment for the five-year project is estimated to be up to $37.5 million.The Multidisciplinary Approach to the Study of Chronic Pelvic Pain (

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-31126924724569911422009-07-22T18:42:00.000-07:002009-07-22T18:44:36.545-07:00

The Center for Science in the Public Interest has notified Bayer Healthcare that it will sue the company if it continues to claim that the selenium in its One A Day vitamins may reduce men’s risk of prostate cancer, the health group announced today.Advertisements and labels for One A Day Men’s 50+ Advantage and One A Day Men’s Health Formula multivitamins claim that "emerging research" suggests

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-58469756725810882002009-07-17T20:53:00.000-07:002009-07-17T20:59:17.505-07:00

Current research is inconclusive regarding the relationship between alcohol consumption and prostate cancer risk. Researchers led by Zhihong Gong Ph.D. of the University of California San Francisco, examined the associations of total alcohol, type of alcoholic beverage, and drinking pattern with risks of total, low- and high-grade prostate cancer.They used data from more than 10,000 men

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-36216059217966268402009-07-11T23:38:00.000-07:002009-07-11T23:39:22.836-07:00

For the last six years, doctors have faced a dilemma about whether to treat men at risk of prostate cancer with the drug finasteride. On one hand, the drug had been shown to prevent cancer in about one of every four patients who received it. On the other, those who did develop cancer while on the drug were 25 percent more likely to have a more aggressive form of the disease. Now new research from

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-5797900753752843032009-07-11T23:36:00.000-07:002009-07-11T23:37:37.823-07:00

An Experimental cancer therapy for prostate cancer may be able to treat men without surgery and offer fewer side effects according to the results of a UK study published in the British Journal of Cancer* today (Wednesday). A group of 172 men with prostate cancer that had not spread were treated under general anaesthetic with High-Intensity-Focused Ultrasound (HIFU) - which uses sound waves to

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-7714221714831897122009-07-11T23:34:00.000-07:002009-07-11T23:35:34.767-07:00

A new 12 month hormone therapy treatment is launched for men with advanced prostate cancer. The Vantas® (histrelin) implant is a small and flexible device, made from the same materials as soft contact lenses. Vantas® is the first 12 month implant to treat prostate cancer to be available in the UK.1Read more at Medical News Today.

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-40476886222991106382009-07-07T07:29:00.000-07:002009-07-07T07:32:35.914-07:00

AbbeyMoor Medical Inc., a developer and manufacturer of medical devices for the management and treatment of prostatic obstruction, announced today that it has received PMA approval from the US Food and Drug Administration (FDA) for design changes to their flagship product, The Spanner Prostatic Stent."These changes are aimed at further improving patient comfort over the current highly accepted

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-74412728883662814712009-07-02T07:36:00.000-07:002009-07-02T07:38:25.133-07:00

Cancer experts at Johns Hopkins say a study tracking 774 prostate cancer patients for a median of eight years has shown that a three-way combination of measurements has the best chance yet of predicting disease metastasis.The new prediction method comprises the length of time it takes for PSA (prostate-specific antigen) to double, Gleason score (a numeric indicator of prostate cancer

LNnoreply@blogger.com1tag:blogger.com,1999:blog-5882683051661659330.post-40302193513401894202009-06-29T19:38:00.000-07:002009-06-29T19:39:14.504-07:00

The July issue of European Urology, the official journal of the European Association of Urology, features an editorial by Lars Holmberg comparing the results from the European Randomised Study of Screening for Prostate Cancer (ERSPC) with the results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO) In the editorial, Professor Holmberg writes that "The studies

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-68932613838695877332009-06-29T07:26:00.001-07:002009-06-29T07:26:57.784-07:00

The recent release of two large randomized trials suggests that if there is a benefit of screening, it is, at best, small, says a new report in CA: A Cancer Journal for Clinicians. Authored by Otis W. Brawley, M.D. of the American Cancer Society and Donna Ankerst, Ph.D. and Ian M. Thompson, M.D. of the University of Texas Health Science Center at San Antonio, the review says because prostate

LNnoreply@blogger.com0tag:blogger.com,1999:blog-5882683051661659330.post-14197356621583990972009-06-26T20:04:00.000-07:002009-06-26T20:06:55.189-07:00

Higher selenium levels in the blood may worsen prostate cancer in some men who already have the disease, according to a study by researchers at Dana-Farber Cancer Institute and the University of California, San Francisco.A higher risk of more-aggressive prostate cancer was seen in men with a certain genetic variant found in about 75 percent of the prostate cancer patients in the study. In those

LNnoreply@blogger.com0